Probing the Existence of a Metastable Binding Site at the β2-Adrenergic Receptor with Homobivalent Bitopic Ligands
Research output: Contribution to journal › Journal article › Research › peer-review
Birgit I Gaiser, Mia Danielsen, Emil Marcher-Rørsted, Kira Røpke Jørgensen, Tomasz M Wróbel, Mikael Frykman, Henrik Johansson, Hans Bräuner-Osborne, David E Gloriam, Jesper Mosolff Mathiesen, Daniel Sejer Pedersen
Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit. Previous molecular dynamics studies on ligand binding to the β2-adrenergic receptor (β2AR) suggested that ligands pause at transient, less-conserved MBSs. We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores. Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized. Pharmacological characterization revealed ligands with similar potency and affinity, slightly increased β2/β1AR-selectivity, and/or substantially slower β2AR off-rates compared to (S)-alprenolol. Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the β2AR, while the linkers alone decreased the potency of the orthosteric fragment. Altogether, the study underlines the potential of targeting MBSs for improving the pharmacological profiles of ligands.
|Journal||Journal of Medicinal Chemistry|
|Number of pages||34|
|Publication status||Published - 12 Sep 2019|